Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilvegostomig + CISGEM in resectable intrahepatic cholangiocarcinoma
NCT07128290Phase 2Not yet recruiting
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Oct 2025
- Primary completion
- Apr 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rilvegostomig in intrahepatic cholangiocarcinoma (ICC), sponsored by Fédération Francophone de Cancérologie Digestive. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
rilvegostomig
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07128290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128290.